AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23975232 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to walk 'at a leisurely pace'
Number of subjects: 24
Study 21392622 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (450/900 mg/d or 1,350/2,250 mg/d)
Number of subjects: 70
Study 21392622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18835608 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnometry-assisted breathing training targeting respiratory dysregulation
Number of subjects: 35
Study 17854242 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 mg with dinner)
Number of subjects: 30
Study 17854242 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (100 mg with dinner and 100 mg with breakfast)
Number of subjects: 30
Study 17854242 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 30
Study 17854242 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 30
Study 15497673 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg sultamicillin tablets (Duobaktam 750 mg tablets)
Number of subjects: 24
Study 15497673 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/5mL sultamicillin suspension (Duobaktam 250 mg/5mL)
Number of subjects: 24
Study 15497673 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary parameter tmax
Number of subjects: 24
Study 11403756 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1000
Study 11403756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 9399753 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (12.5 mg weekly)
Number of subjects: 84
Study 9399753 — intervention group
Group type: COMPARATOR
Intervention: 6-mercaptopurine (50 mg daily)
Number of subjects: 84
Study 9399753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 7954556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 20
Study 7954556 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5 mg)
Number of subjects: 20
Study 3665340 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 15
Study 3665340 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 15
Study 3665340 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving anticonvulsant therapy)
Number of subjects: 15
Study 3665340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of prednisone and methylprednisolone
Number of subjects: 15
Study 3665340 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of anticonvulsant therapy
Number of subjects: 15
Study 3665340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination anticonvulsant therapy
Number of subjects: 15
Study 29494398 — intervention group
Group type: EXPERIMENTAL
Intervention: RANK expression in parotid gland carcinomas
Number of subjects: 46
Study 29494398 — intervention group
Group type: EXPERIMENTAL
Intervention: RANKL expression in parotid gland carcinomas
Number of subjects: 46
Study 29494398 — intervention group
Group type: COMPARATOR
Intervention: RANK expression in parotid gland adenomas
Number of subjects: 46
Study 29494398 — intervention group
Group type: COMPARATOR
Intervention: RANKL expression in parotid gland adenomas
Number of subjects: 46
Study 29494398 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RANK/RANKL expression between carcinomas and adenomas
Number of subjects: 46
Study 27410242 — intervention group
Group type: EXPERIMENTAL
Intervention: One valid cue
Number of subjects: 240
Study 27410242 — intervention group
Group type: EXPERIMENTAL
Intervention: Two valid cues
Number of subjects: 240
Study 27410242 — intervention group
Group type: EXPERIMENTAL
Intervention: Three valid cues
Number of subjects: 240
Study 27410242 — intervention group
Group type: EXPERIMENTAL
Intervention: All valid cues
Number of subjects: 240
Study 27410242 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 240
Study 27410242 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants
Number of subjects: 240
Study 24622830 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (4.7% vol, 400 ml)
Number of subjects: 12
Study 24622830 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (13.7% vol, 200 ml)
Number of subjects: 12
Study 24622830 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisky (43.5% vol, 100 ml)
Number of subjects: 12
Study 24622830 — intervention group
Group type: COMPARATOR
Intervention: Isotonic glucose solution
Number of subjects: 12
Study 24622830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol solutions of identical proof
Number of subjects: 12
Study 24622830 — intervention group
Group type: EXPERIMENTAL
Intervention: High proof ethanol
Number of subjects: 12
Study 24622830 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine and whisky
Number of subjects: 12
Study 24622830 — intervention group
Group type: COMPARATOR
Intervention: Control ethanol solutions
Number of subjects: 12
Study 23482332 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal motivation (patient-oriented brochure)
Number of subjects: 50
Study 23482332 — intervention group
Group type: EXPERIMENTAL
Intervention: External motivation (physician letter of recommendation)
Number of subjects: 50
Study 23482332 — intervention group
Group type: COMPARATOR
Intervention: Control (generic referral card)
Number of subjects: 50
Study 23482332 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal motivation
Number of subjects: 50
Study 21538388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 20
Study 21538388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18364344 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention
Number of subjects: 213
Study 18364344 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 213
Study 16311751 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial therapy (BT; n=31)
Number of subjects: 64
Study 16311751 — intervention group
Group type: COMPARATOR
Intervention: Conventional biomedical therapy (MT; n=33)
Number of subjects: 64
Study 12747192 — intervention group
Group type: EXPERIMENTAL
Intervention: Kang Wei Granules
Number of subjects: 288
Study 12747192 — intervention group
Group type: COMPARATOR
Intervention: De Nol triple therapy
Number of subjects: 288
Study 10802993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 39
Study 10802993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8607332 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (oral anticoagulants replaced with heparin from 6 to 12 weeks, vitamin K antagonists during second and third trimesters, heparin after 36 weeks until 10 days postpartum)
Number of subjects: 54
Study 8607332 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be those not receiving anticoagulant therapy)
Number of subjects: 54
Study 1592844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 27
Study 1592844 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 27
Study 1592844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3894257 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid 600 mg daily
Number of subjects: 68
Study 3894257 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 75 mg daily
Number of subjects: 68
Study 31451342 — intervention group
Group type: EXPERIMENTAL
Intervention: arthrocentesis plus HA (group Ia)
Number of subjects: 90
Study 31451342 — intervention group
Group type: EXPERIMENTAL
Intervention: single HA (group Ib)
Number of subjects: 90
Study 31451342 — intervention group
Group type: COMPARATOR
Intervention: control (group Ic)
Number of subjects: 90
Study 31451342 — intervention group
Group type: EXPERIMENTAL
Intervention: arthrocentesis plus HA (group IIa)
Number of subjects: 90
Study 31451342 — intervention group
Group type: EXPERIMENTAL
Intervention: single HA (group IIb)
Number of subjects: 90
Study 31451342 — intervention group
Group type: COMPARATOR
Intervention: control (group IIc)
Number of subjects: 90
Study 29854436 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 49
Study 29854436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 26409247 — intervention group
Group type: EXPERIMENTAL
Intervention: Free pregnancy test kits provided to CHWs (treatment group)
Number of subjects: 622
Study 26409247 — intervention group
Group type: COMPARATOR
Intervention: No pregnancy test kits provided to CHWs (control group)
Number of subjects: 622
Study 24628950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy with oxaliplatin
Number of subjects: 306
Study 24628950 — intervention group
Group type: COMPARATOR
Intervention: Perioperative systemic chemotherapy and D1-D2 curative gastrectomy
Number of subjects: 306
Study 24628950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary study comparing incidence of positive peritoneal cytology pre- and post-gastrectomy
Number of subjects: 306
Study 22814006 — intervention group
Group type: EXPERIMENTAL
Intervention: Perazine
Number of subjects: 191
Study 22814006 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 191
Study 22814006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 191
Study 22814006 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 191
Study 21224795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track management (whole)
Number of subjects: 75
Study 21224795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track management (partial)
Number of subjects: 75
Study 21224795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track management (postoperative only)
Number of subjects: 75
Study 18278775 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA 1 (stepwise laser withdrawal)
Number of subjects: 101
Study 18278775 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA 2 (continuous laser withdrawal)
Number of subjects: 101
Study 18278775 — intervention group
Group type: COMPARATOR
Intervention: Surgery (saphenofemoral ligation, GSV stripping, multiple phlebectomies)
Number of subjects: 101
Study 18278775 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA 1
Number of subjects: 101
Study 18278775 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA 2
Number of subjects: 101
Study 18278775 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 101
Study 18278775 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA (both methods)
Number of subjects: 101
Study 15608044 — intervention group
Group type: COMPARATOR
Intervention: Control group (group L, n=21) received i.v. saline
Number of subjects: 60
Study 15608044 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural tramadol group (group T, n=20) received i.v. saline and PCB with tramadol 1.5 mg kg(‐1)
Number of subjects: 60
Study 15608044 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic tramadol group (group IT, n=19) received i.v. tramadol 1.5 mg kg(‐1)
Number of subjects: 60
Study 11854391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus vinorelbine
Number of subjects: 0
Study 11854391 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel
Number of subjects: 0
Study 10354830 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative removal of high-grade carotid stenoses
Number of subjects: 250000
Study 10354830 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid thrombarterectomy (TEA)
Number of subjects: 250000
Study 10354830 — intervention group
Group type: COMPARATOR
Intervention: Interventional methods (stent, PTA)
Number of subjects: 250000
Study 8530798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontapering course of prednisone
Number of subjects: 76
Study 8530798 — intervention group
Group type: COMPARATOR
Intervention: Tapering course of prednisone (historical control)
Number of subjects: 76
Study 2121653 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up (WU trial) consisting of a 400‐m front crawl swim (82% VO2max), 400‐m flutter kicking (45% VO2max), and 4 x 50‐m front crawl sprints (111% VO2max)
Number of subjects: 8
Study 2121653 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up (WU trial)
Number of subjects: 8
Study 2121653 — intervention group
Group type: COMPARATOR
Intervention: No warm-up (NWU trial)
Number of subjects: 8
Study 675854 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radical or extended radical mastectomy
Number of subjects: 716
Study 28704841 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 3114
Study 28704841 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥ 35 kg m-2
Number of subjects: 3114
Study 28704841 — intervention group
Group type: COMPARATOR
Intervention: Physical activity in the third quartile
Number of subjects: 3114
Study 28704841 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking, high BMI, and high alcohol consumption
Number of subjects: 3114
Study 25993883 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine before resistance training (CR-B)
Number of subjects: 39
Study 25993883 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine after resistance training (CR-A)
Number of subjects: 39
Study 25993883 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (both CR-B and CR-A)
Number of subjects: 39
Study 25993883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 39
Study 23117723 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration enoxaparin prophylaxis (40 mg daily for 28±4 days)
Number of subjects: 389
Study 23117723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 21797984 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided mesh insertion
Number of subjects: 60
Study 21797984 — intervention group
Group type: EXPERIMENTAL
Intervention: Native tissue repair
Number of subjects: 60
Study 19558471 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPD method using CA1 primer
Number of subjects: 57
Study 19558471 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPD method using CA2 primer
Number of subjects: 57
Study 19558471 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPD method using both CA1 and CA2 primers
Number of subjects: 57
Study 19558471 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEF karyotyping
Number of subjects: 57
Study 17034954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone (400mg)
Number of subjects: 15
Study 17034954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14523053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg q.d.
Number of subjects: 8
Study 14523053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg q.d.
Number of subjects: 8
Study 14523053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Fenofibrate
Number of subjects: 8
Study 11215603 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dk/t silicone hydrogel lenses (lotrafilcon A) worn for 30 nights
Number of subjects: 127
Study 11215603 — intervention group
Group type: COMPARATOR
Intervention: Low Dk/t HEMA-based lenses (etafilcon A) worn for 6 nights
Number of subjects: 127
Study 9517650 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (group A) at 4 hours after PEG placement
Number of subjects: 112
Study 9517650 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding (group B) at 24 hours after PEG placement
Number of subjects: 112
Study 11271244 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (3200 mg/day if creatinine clearance > 50 ml/min, intravenously for first 90 days)
Number of subjects: 37
Study 11271244 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control group)
Number of subjects: 37
Study 11271244 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 37
Study 3051990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 to 180 mg twice daily)
Number of subjects: 132
Study 3051990 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 to 75 mg twice daily)
Number of subjects: 132
Study 3051990 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem and Captopril in combination
Number of subjects: 132
Study 15177815 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect patients
Number of subjects: 0
Study 15177815 — intervention group
Group type: COMPARATOR
Intervention: Healthy and patient controls
Number of subjects: 0
Study 31568130 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR1 SNP (TT)
Number of subjects: 124
Study 31568130 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR1 STR (<17 repeats)
Number of subjects: 124
Study 31568130 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR1 (c.‐397T>C with (TA)n=17)
Number of subjects: 124
Study 31568130 — intervention group
Group type: EXPERIMENTAL
Intervention: AMHR2 (AA)
Number of subjects: 124
Study 28703727 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected samples for STI testing
Number of subjects: 1113
Study 25623246 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexterity training program
Number of subjects: 39
Study 25623246 — intervention group
Group type: COMPARATOR
Intervention: Theraband training program
Number of subjects: 39
Study 23599221 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight-supported treadmill training (BWSTT)
Number of subjects: 50
Study 23599221 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 50
Study 21365044 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium oxide abutments
Number of subjects: 0
Study 21365044 — intervention group
Group type: COMPARATOR
Intervention: Titanium alloy abutments
Number of subjects: 0
Study 19488955 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cesarean delivery with spinal anesthesia
Number of subjects: 164
Study 19488955 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cesarean delivery with general anesthesia
Number of subjects: 164
Study 19488955 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated vaginal delivery with local anesthesia
Number of subjects: 164
Study 19488955 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated vaginal delivery with spinal saddle block
Number of subjects: 164
Study 17348223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity ultrasound treatment
Number of subjects: 40
Study 17348223 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 15242993 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 100
Study 15242993 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 100
Study 10945198 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic venous drainage (SV group)
Number of subjects: 34
Study 10945198 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal venous drainage (PV group)
Number of subjects: 34
Study 10945198 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SV and PV)
Number of subjects: 34
Study 9309988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 100 micrograms twice daily
Number of subjects: 274
Study 9309988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 micrograms twice daily
Number of subjects: 274
Study 9309988 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluticasone propionate 20 mg once daily
Number of subjects: 274
Study 9309988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 8318328 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of anaesthesia with propofol 3‐5 mg kg‐1 followed by maintenance with halothane and an appropriate regional block
Number of subjects: 40
Study 8318328 — intervention group
Group type: COMPARATOR
Intervention: Induction and maintenance of anaesthesia with a computerized, target‐controlled infusion of propofol with a regional block
Number of subjects: 40
Study 8318328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 2882769 — intervention group
Group type: EXPERIMENTAL
Intervention: neostigmine 0.07 mg kg‐1
Number of subjects: 39
Study 2882769 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium 0.8 mg kg‐1
Number of subjects: 39
Study 2882769 — intervention group
Group type: COMPARATOR
Intervention: control value
Number of subjects: 39
Study 28346315 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Training (INT)
Number of subjects: 94
Study 28346315 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 94
Study 27870712 — intervention group
Group type: EXPERIMENTAL
Intervention: Irosustat 40 mg/d
Number of subjects: 71
Study 27870712 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate 160 mg/d
Number of subjects: 71
Study 26455890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount, low-intensity exercise (LALI) - 180 kcal/session for women, 300 kcal/session for men at 50% of CRF; n=39
Number of subjects: 121
Study 26455890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount, low-intensity exercise (HALI) - 360 kcal/session for women, 600 kcal/session for men at 50% of CRF; n=51
Number of subjects: 121
Study 26455890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount, high-intensity exercise (HAHI) - 360 kcal/session for women, 600 kcal/session for men at 75% of CRF; n=31
Number of subjects: 121
Study 26455890 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing exercise amount at fixed intensity
Number of subjects: 121
Study 26455890 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing exercise intensity at fixed amount
Number of subjects: 121
Study 23620190 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger Awareness and Expression Training (AAET)
Number of subjects: 147
Study 23620190 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 147
Study 23620190 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 147